GlassScriptPhysician profile
Michael R Grunwald
NPI 1356495949
$343,614.77
in general payments reported to CMS, 2019-2025
35 companies · $64K in 2025
The $64K reported for 2025 was more than what 96% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $52K · 2021: $93K · 2022: $41K · 2023: $21K · 2024: $45K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $109K · Travel and Lodging: $10K · Food and Beverage: $5,692 · Honoraria: $5,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $108,768.32 |
| Travel and Lodging | $10,013.54 |
| Food and Beverage | $5,692.02 |
| Honoraria | $5,436.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $97,570.87 | 2019-2025 | Vanflyta |
| Incyte Corporation | $70,603.73 | 2019-2025 | Niktimvo, Jakafi, Niktimvo |
| Pfizer INC. | $19,196.49 | 2019-2024 | |
| Celgene Corporation | $16,619.45 | 2020-2023 | |
| Astellas Pharma Global Development | $16,430.00 | 2020-2023 | Xospata |
| Sobi, INC | $15,988.14 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $10,045.88 | 2024 | |
| Geron Corporation | $7,611.88 | 2025 | Imetelstat, Rytelo |
| Amgen INC. | $6,971.82 | 2019-2025 | Blincyto, Blincyto |
| Blueprint Medicines Corporation | $6,025.02 | 2021-2024 | |
| Astellas Pharma US INC | $5,908.46 | 2022-2023 | Xospata |
| Cti Biopharma Corp. | $5,861.09 | 2022-2023 | Vonjo |
| Stemline Therapeutics INC. | $5,650.00 | 2021-2022 | |
| Genzyme Corporation | $5,561.50 | 2019-2024 | |
| Servier Pharmaceuticals LLC | $5,220.00 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $5,182.84 | 2022 | |
| Shorla Oncology INC. | $4,950.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,512.63 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,207.72 | 2025 | |
| Glaxosmithkline, LLC. | $4,081.98 | 2022 | |
| Autolus INC | $3,819.77 | 2025 | |
| Agios Pharmaceuticals, INC. | $3,502.45 | 2020 | |
| Abbvie INC. | $2,775.00 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $2,714.11 | 2021 | |
| Jazz Pharmaceuticals INC. | $2,560.00 | 2022 | |
| Sanofi US Services INC. | $2,314.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,146.56 | 2022-2024 | |
| Gilead Sciences, INC. | $1,930.00 | 2020 | |
| National Marrow Donor Program | $1,926.85 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $1,158.74 | 2024 | |
| Alexion Pharmaceuticals, INC. | $400.00 | 2019-2022 | |
| Neuronetics, INC. | $106.33 | 2024 | Neurostar Tms Therapy System |
| Kite Pharma, INC. | $49.13 | 2024 | Yescarta |
| Janssen Biotech, INC. | $11.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grunwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.